Assessing the risk of attack in the management of asthma: A review and proposal for revision of the current control-centred paradigm

Primary Care Respiratory Journal

Volumn 22, Issue 3, 2013, Pages 344-352

  Blakey, John D ^a   Woolnough, Kerry ^b   Fellows, Jodie ^b,c   Walker, Samantha ^d   Thomas, Mike ^e   Pavord, Ian D ^f  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^d ASTHMA UK   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Asthma attack; Asthma control; Asthma guidelines; Management; Risk

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MEPOLIZUMAB; MONTELUKAST; SHORT ACTING DRUG; STEROID; THEOPHYLLINE; XANTHINE DERIVATIVE;

ASTHMA; BRONCHIAL THERMOPLASTY; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG MEGADOSE; HEALTH PROGRAM; HUMAN; LUNG EMPHYSEMA; LUNG INJURY; MORBIDITY; MOTIVATIONAL INTERVIEWING; NATIONAL HEALTH SERVICE; PATIENT DECISION MAKING; PEAK EXPIRATORY FLOW; PERSONALIZED MEDICINE; PHENOTYPE; PHYSICAL MEDICINE; PHYSIOTHERAPY; PRACTICE GUIDELINE; RESPIRATION CONTROL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SMOKING CESSATION; SPIROMETRY; TOTAL QUALITY MANAGEMENT; UNSPECIFIED SIDE EFFECT;

ASTHMA; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; PRIMARY HEALTH CARE; RISK ASSESSMENT;

EID: 84883458047     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2013.00063     Document Type: Review

References (118)

1. Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127(2):355-60. http://dx.doi.org/10.1016/j.jaci.2010.11.037
2. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet 2010;376(9743):803-13. http://dx.doi.org/10.1016/S0140-6736(10)61087-2
3. Wang F, He XY, Baines KJ, et al. Different inflammatory phenotypes in adults and children with acute asthma. Eur Respir J 2011;38(3):567-74. http://dx.doi.org/10.1183/09031936.00170110
4. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000;16(3):432-6. http://dx.doi.org/10.1034/j.1399-3003.2000.016003432.x
5. Strachan DP, Butland BK, Anderson HR. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. BMJ 1996;312(7040):1195-9. http://dx.doi.org/10.1136/bmj.312.7040.1195
6. Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J R Soc Med 2010;103(3):98-106. http://dx.doi.org/10.1258/jrsm.2009.090348
7. Tsai CL, Lee WY, Hanania NA, Camargo CA, Jr. Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008. J Allergy Clin Immunol 2012;129(5):1252el-1258e1.
8. Bateman ED, Reddel HK, Eriksson G, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010;125(3):600-608+8e1-8e6.
9. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178(3):218-24. http://dx.doi.org/10.1164/rccm.200711-1754OC
10. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126(5):926-38. http://dx.doi.org/10.1016/j.jaci.2010.07.019
11. Fitzgerald JM. Targeting lung attacks. Thorax 2011;66(5):365-6. http://dx.doi.org/10.1136/thx.2010.156760
12. Anderson HR, Gupta R, Strachan DP, Limb ES. 50 years of asthma: UK trends from 1955 to 2004. Thorax 2007;62(1):85-90. http://dx.doi.org/10.1136/thx.2006.066407
13. Moorman JE, Rudd RA, Johnson CA, et al. National surveillance for asthma: United States, 1980-2004. MMWR CDC Surveill Summ 2007;56(SS08):18-54.
14. The NHS Information Centre. Inpatient statistics, 2010-11. 2012. Available from: http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=202.
15. Price D, Haughney J, Sims E, et al. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. J Asthma Allergy 2011;4:37-47.
16. Tata LJ, West J, Harrison T, Farrington P, Smith C, Hubbard R. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax 2003;58(10):835-9. http://dx.doi.org/10.1136/thorax.58.10.835
17. Turner S, Thomas M, von Ziegenweidt J, Price D. Prescribing trends in asthma: a longitudinal observational study. Arch Dis Child 2009;94(1):16-22. http://dx.doi.org/10.1136/adc.2008.140681
18. Mori H, Tanaka H, Ohno Y, et al. Effect of intermittent systemic corticosteroid on bone metabolism in bronchial asthma patients. J Asthma 2009;46(2):142-6. http://dx.doi.org/10.1080/02770900802492095
19. Cumming RG, Mitchell P. Inhaled corticosteroids and cataract: prevalence, prevention and management. Drug Saf 1999;20(1):77-84. http://dx.doi.org/10.2165/00002018-199920010-00007
20. Thomas M, Bruton A, Moffat M, Cleland J. Asthma and psychological dysfunction. Prim Care Respir J 2011;20(3):250-6. http://dx.doi.org/10.4104/pcrj.2011.00058
21. Asthma UK. Fighting for Breath. London: Asthma UK, 2010.
22. Hasler G, Gergen PJ, Kleinbaum DG, et al. Asthma and panic in young adults: a 20-year prospective community study. Am J Respir Crit Care Med 2005;171(11):1224-30. http://dx.doi.org/10.1164/rccm.200412-1669OC
23. Weiser EB. The prevalence of anxiety disorders among adults with asthma: a meta-analytic review. J Clin Psychol Med Settings 2007;14(4):297-307. http://dx.doi.org/10.1007/s10880-007-9087-2
24. Greaves CJ, Eiser C, Seamark D, Halpin DM. Attack context: an important mediator of the relationship between psychological status and asthma outcomes. Thorax 2002;57(3):217-21. http://dx.doi.org/10.1136/thorax.57.3.217
25. Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003;349(15):1414-22. http://dx.doi.org/10.1056/NEJMoa022363
26. Oswald H, Phelan PD, Lanigan A, et al. Childhood asthma and lung function in mid-adult life. Pediatr Pulmonol 1997;23(1):14-20. http://dx.doi.org/10.1002/(SICI)1099-0496(199701)23:114::AID-PPUL23.0.CO;2-P
27. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005;171(2):109-14. http://dx.doi.org/10.1164/rccm.200402-230OC
28. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998;339(17):1194-200. http://dx.doi.org/10.1056/NEJM199810223391703
29. Strunk RC, Weiss ST, Yates KP, Tonascia J, Zeiger RS, Szefler SJ. Mild to moderate asthma affects lung growth in children and adolescents. J Allergy Clin Immunol 2006;118(5):1040-7. http://dx.doi.org/10.1016/j.jaci.2006.07.053
30. Selroos O, Pietinalho A, Lofroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995;108(5):1228-34. http://dx.doi.org/10.1378/chest.108.5.1228
31. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325(6):388-92. http://dx.doi.org/10.1056/NEJM199108083250603
32. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007;30(3):452-456. http://dx.doi.org/10.1183/09031936.00165106
33. van Veen IH, Ten Brinke A, Sterk PJ, et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 2008;32(2):344-349. http://dx.doi.org/10.1183/09031936.00135907
34. Rossi E, Scano G. Association of sputum parameters with clinical and functional measurements in asthma. Thorax 2000;55:235-238. http://dx.doi.org/10.1136/thorax.55.3.235
35. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009;179(1):19-24. http://dx.doi.org/10.1164/rccm.200807-1126OC
36. Gonem S, Umar I, Burke D, et al. Airway impedance entropy and exacerbations in severe asthma. Eur Respir J 2012;40(5):1156-1163. http://dx.doi.org/10.1183/09031936.00228611
37. Shi Y, Aledia AS, Galant SP, George SC. Peripheral airway impairment measured by oscillometry predicts loss of asthma control in children. J Allergy Clin Immunol 2013;131(3):718-723. http://dx.doi.org/10.1016/j.jaci.2012.09.022
38. Harrison B, Stephenson P, Mohan G, Nasser S. An ongoing Confidential Enquiry into asthma deaths in the Eastern Region of the UK, 2001-2003. Prim Care Respir J 2005;14(6):303-313. http://dx.doi.org/10.1016/j.pcrj.2005.08.004
39. Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol 2000;106(3):493-499. http://dx.doi.org/10.1067/mai.2000.109426
40. Kamble S, Bharmal M. Incremental direct expenditure of treating asthma in the United States. J Asthma 2009;46(1):73-80. http://dx.doi.org/10.1080/02770900802503107
41. Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009;9:24. http://dx.doi.org/10.1186/1471-2466-9-24
42. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113(1):59-65. http://dx.doi.org/10.1016/j.jaci.2003.09.008
43. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14(4):902-907. http://dx.doi.org/10.1034/j.1399-3003.1999.14d29.x
44. Thomas M, Gruffydd-Jones K, Stonham C, Ward S, Macfarlane TV. Assessing asthma control in routine clinical practice: use of the Royal College of Physicians '3 questions'. Prim Care Respir J 2009;18(2):83-88. http://dx.doi.org/10.3132/pcrj.2008.00045
45. Sato R, Tomita K, Sano H, et al. The strategy for predicting future exacerbation of asthma using a combination of the Asthma Control Test and lung function test. J Asthma 2009;46(7):677-682. http://dx.doi.org/10.1080/02770900902972160
46. Meltzer EO, Busse WW, Wenzel SE, et al. Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol 2011;127(1):167-172. http://dx.doi.org/10.1016/j.jaci.2010.08.042
47. Peters D, Chen C, Markson LE, Allen-Ramey FC, Vollmer WM. Using an asthma control questionnaire and administrative data to predict health-care utilization. Chest 2006;129(4):918-24. http://dx.doi.org/10.1378/chest.129.4.918
48. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet 1999;353(9150):364-9. http://dx.doi.org/10.1016/S0140-6736(98)06128-5
49. Lundback B, Dahl R. Assessment of asthma control and its impact on optimal treatment strategy. Allergy 2007;62(6):611-619. http://dx.doi.org/10.1111/j.1398-9995.2007.01399.x
50. Schatz M, Zeiger RS, Yang SJ, et al. Relationship of asthma control to asthma exacerbations using surrogate markers within a managed care database. Am J Manag Care 2010;16(5):327-333.
51. Osborne ML, Pedula KL, O'Hollaren M, et al. Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. Chest 2007;132(4):1151-1161. http://dx.doi.org/10.1378/chest.05-3084
52. Kitch BT, Paltiel AD, Kuntz KM, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 2004;126(6):1875-82. http://dx.doi.org/10.1378/chest.126.6.1875
53. Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 2010;65(9):787-94. http://dx.doi.org/10.1136/thx.2010.137414
54. Wenzel S. Characteristics, definition and phenotypes of severe asthma. In: Chung KF, Bel E, Wenzel S, eds. ERS Monograph: Difficult-to-Treat Severe Asthma. 51: European Respiratory Society, 2011.
55. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006;(2):35-59.
56. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367(13):1198-207. http://dx.doi.org/10.1056/NEJMoa1208606
57. Low K, Lau KK, Holmes P, et al. Abnormal vocal cord function in difficult-to-treat asthma. Am J Respir Crit Care Med 2011;184(1):50-6. http://dx.doi.org/10.1164/rccm.201010-1604OC
58. Castro M, Zimmermann NA, Crocker S, Bradley J, Leven C, Schechtman KB. Asthma intervention program prevents readmissions in high healthcare users. Am J Respir Crit Care Med 2003;168(9):1095-1099. http://dx.doi.org/10.1164/rccm.200208-877OC
59. Souza-Machado C, Souza-Machado A, Franco R, et al. Rapid reduction in hospitalisations after an intervention to manage severe asthma. Eur Respir J 2010;35(3):515-21. http://dx.doi.org/10.1183/09031936.00101009
60. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170(8):836-44. http://dx.doi.org/10.1164/rccm.200401-033OC
61. Blakey JD, Wardlaw AJ. What is severe asthma? Clin Exp Allergy 2012;42(5):617-24. http://dx.doi.org/10.1111/j.1365-2222.2012.03962.x
62. Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011;66(10):910-17. http://dx.doi.org/10.1136/thx.2010.153643
63. Romagnoli M, Caramori G, Braccioni F, et al. Near-fatal asthma phenotype in the ENFUMOSA cohort. Clin Exp Allergy 2007;37(4):552-7. http://dx.doi.org/10.1111/j.1365-2222.2007.02683.x
64. Miller MK, Lee JH, Blanc PD, et al. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J 2006;28(6):1145-55. http://dx.doi.org/10.1183/09031936.06.00145105
65. Chilmonczyk BA, Salmun LM, Megathlin KN, et al. Association between exposure to environmental tobacco smoke and exacerbations of asthma in children. N Engl J Med 1993;328(23):1665-9. http://dx.doi.org/10.1056/NEJM199306103282303
66. Comhair SA, Gaston BM, Ricci KS, et al. Detrimental effects of environmental tobacco smoke in relation to asthma severity. PLoS One 2011;6(5):e18574. http://dx.doi.org/10.1371/journal.pone.0018574
67. Eisner MD, Klein J, Hammond SK, Koren G, Lactao G, Iribarren C. Directly measured second hand smoke exposure and asthma health outcomes. Thorax 2005;60(10):814-21. http://dx.doi.org/10.1136/thx.2004.037283
68. Lasmar L, Camargos P, Champs NS, et al. Adherence rate to inhaled corticosteroids and their impact on asthma control. Allergy 2009;64(5):784-9. http://dx.doi.org/10.1111/j.1398-9995.2008.01877.x
69. Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011;128(6):1185el-1191e2.
70. Watson JP, Cowen P, Lewis RA. The relationship between asthma admission rates, routes of admission, and socioeconomic deprivation. Eur Respir J 1996;9(10):2087-93. http://dx.doi.org/10.1183/09031936.96.09102087
71. Bacon SL, Bouchard A, Loucks EB, Lavoie KL. Individual-level socioeconomic status is associated with worse asthma morbidity in patients with asthma. Respir Res 2009;10:125. http://dx.doi.org/10.1186/1465-9921-10-125
72. ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005;26(5):812-18. http://dx.doi.org/10.1183/09031936.05.00037905
73. Bousquet J, Gaugris S, Kocevar VS, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. Clin Exp Allergy 2005;35(6):723-7. http://dx.doi.org/10.1111/j.1365-2222.2005.02251.x
74. Black PN, Udy AA, Brodie SM. Sensitivity to fungal allergens is a risk factor for life-threatening asthma. Allergy 2000;55(5):501-04. http://dx.doi.org/10.1034/j.1398-9995.2000.00293.x
75. Haselkorn T, Fish JE, Chipps BE, Miller DP, Chen H, Weiss ST. Effect of weight change on asthma-related health outcomes in patients with severe or difficult-to-treat asthma. Respir Med 2009;103(2):274-83. http://dx.doi.org/10.1016/j.rmed.2008.08.010
76. Kattan M, Kumar R, Bloomberg GR, et al. Asthma control, adiposity, and adipokines among inner-city adolescents. J Allergy Clin Immunol 2010;125(3):584-92. http://dx.doi.org/10.1016/j.jaci.2010.01.053
77. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372(9643):1107-19. http://dx.doi.org/10.1016/S0140-6736(08)61452-X
78. Postma D, Anzueto A, Calverley P, et al. A new perspective on optimal care for patients with COPD. Prim Care Respir J 2011;20(2):205-09. http://dx.doi.org/10.4104/pcrj.2011.00041
79. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012;186(1):48-55. http://dx.doi.org/10.1164/rccm.201108-1553OC
80. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184(6):662-71. http://dx.doi.org/10.1164/rccm.201104-0597OC
81. Pavord ID, Wardlaw AJ. The A to E of airway disease. Clin Exp Allergy 2010;40(1):62-7. http://dx.doi.org/10.1111/j.1365-2222.2009.03410.x
82. Gonem S, Raj V, Wardlaw AJ, Pavord ID, Green R, Siddiqui S. Phenotyping airways disease: an A to E approach. Clin Exp Allergy 2011;42(12):1664-83. http://dx.doi.org/10.1111/j.1365-2222.2012.04008.x
83. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181(4):315-23. http://dx.doi.org/10.1164/rccm.200906-0896OC
84. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360(9347):1715-21. http://dx.doi.org/10.1016/S0140-6736(02)11679-5
85. Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol 1989;56(2):267-83. http://dx.doi.org/10.1037/0022-3514.56.2.267
86. Yellowlees PM, Ruffin RE. Psychological defenses and coping styles in patients following a life-threatening attack of asthma. Chest 1989;95(6):1298-303.
87. Campbell DA, Yellowlees PM, McLennan G, et al. Psychiatric and medical features of near fatal asthma. Thorax 1995;50(3):254-9. http://dx.doi.org/10.1136/thx.50.3.254
88. Nazarian D, Smyth JM, Sliwinski MJ. A naturalistic study of ambulatory asthma severity and reported avoidant coping styles. Chronic Illn 2006;2(1):51-8.
89. Cooke L, Myers L, Derakshan N. Lung function, adherence and denial in asthma patients who exhibit a repressive coping style. Psychol Health Med 2003;8(1):35-44. http://dx.doi.org/10.1080/1354850021000059241
90. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2008;63(Suppl 4): 1-121. http://dx.doi.org/10.1136/thx.2008.097741
91. Seddon P, Bara A, Ducharme FM, Lasserson TJ. Oral xanthines as maintenance treatment for asthma in children. Cochrane Database Syst Rev 2006 (1):28-85.
92. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337(20):1405-11. http://dx.doi.org/10.1056/NEJM199711133372001
93. Boyle RJ, Pedroletti C, Wickman M, et al. Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial. Thorax 2012;67(3):215-21. http://dx.doi.org/10.1136/thoraxjnl-2011-200665
94. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010;181(2):116-24. http://dx.doi.org/10.1164/rccm.200903-0354OC
95. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380(9842):651-9. http://dx.doi.org/10.1016/S0140-6736(12)60988-X
96. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176(11):1062-71. http://dx.doi.org/10.1164/rccm.200701-085OC
97. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360(10):973-84. http://dx.doi.org/10.1056/NEJMoa0808991
98. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360(10):985-93. http://dx.doi.org/10.1056/NEJMoa0805435
99. Hubbard R, Tattersfield A, Smith C, West J, Smeeth L, Fletcher A. Use of inhaled corticosteroids and the risk of fracture. Chest 2006;130(4):1082-8. http://dx.doi.org/10.1378/chest.130.4.1082
100. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010;362(13):1169-71. http://dx.doi.org/10.1056/NEJMp1002074
101. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium: the FDA's conclusions. N Engl J Med 2010;363(12):1097-9. http://dx.doi.org/10.1056/NEJMp1008502
102. O'Neill S, Sweeney J, Neill CO, et al. The cost of refractory asthma in the UK: A preliminary analysis. Thorax 2012;67(Suppl 2):A32. http://dx.doi.org/10.1136/thoraxjnl-2012-202678.070
103. Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003;326(7399):1115. http://dx.doi.org/10.1136/bmj.326.7399.1115
104. Bodzenta-Lukaszyk A, Dymek A, McAulay K, Mansikka H. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med 2011;11:28. http://dx.doi.org/10.1186/1471-2466-11-28
105. Sugihara N, Kanada S, Haida M, et al. 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol. Respir Med 2010;104(11):1629-37. http://dx.doi.org/10.1016/j.rmed.2010.06.011
106. Feldman G, Walker RR, Brooks J, Mehta R, Crater G. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther 2012;25(6):465-71. http://dx.doi.org/10.1016/j.pupt.2012.08.007
107. Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 2012;142(1):119-27. http://dx.doi.org/10.1378/chest.11-2231
108. Walsh S, Hagan T, Gamsu D. Rescuer and rescued: applying a cognitive analytic perspective to explore the 'mis-management' of asthma. Br J Med Psychol 2000;73(Pt 2):151-68. http://dx.doi.org/10.1348/000711200160390
109. Blakey JD, Obediat M, Pogson Z, Sayers I, Hall IP. A simple asthma severity score predicts exacerbations. American Thoracic Society; Denver, Colorado, 2011. p. A2248.
110. Asthma UK. The Triple A test 2012. Available from:http://www.asthma.org.uk/get-involved/our-campaigns/the-triple-a-avoid-asthma-attacks-campaign/.
111. Blakey J, Woulnough K, Walker S, et al. The asthma UK risk assessment project (AURA) phase two: systematic review of risk factors for asthma exacerbation. York: NIHR, 2012. Available from:http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002338
112. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002;19(2):246-51. http://dx.doi.org/10.1183/09031936.02.00218402
113. Spiegelhalter D, Pearson M, Short I. Visualizing uncertainty about the future. Science 2011;333(6048):1393-400. http://dx.doi.org/10.1126/science.1191181
114. Horne R, Price D, Cleland J, et al. Can asthma control be improved by understanding the patient's perspective? BMC Pulm Med 2007;7:8. http://dx.doi.org/10.1186/1471-2466-7-8
115. Krones T, Keller H, Sadowski E. Absolute cardiovascular disease risk and shared decision making in primary care: a randomized controlled trial. Ann Fam Med 2008;6(3):218-27. http://dx.doi.org/10.1370/afm.854
116. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008;336:598. http://dx.doi.org/10.1136/bmj.39503.582396.25
117. Gamble J, Stevenson M, Heaney LG. A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respir Med 2011;105(9):1308-15. http://dx.doi.org/10.1016/j.rmed.2011.03.019
118. Schmaling KB, Blume A, Afari N. A randomized controlled pilot study of motivational interviewing to change attitudes about adherence to medications for asthma. J Clin Psychol Med Settings 2001;8(3):167-72. http://dx.doi.org/10.1023/A:1011365519345